Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRB-061 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis
NCT06934252Phase 1Recruiting
- Sponsor
- TRexBio
- Start
- May 2025
- Primary completion
- Sep 2027
- Modality
- Biologic
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of TRB-061 in atopic dermatitis (AD) (4 arms), sponsored by TRexBio. Primary endpoint: Incidence of Adverse Events and Serious Adverse Events at Day 253. Started May 2025; status: recruiting.
02
Drugs
TRB-061
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06934252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06934252.